Abstract
Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.
Keywords: Demyelinating disease, pediatric multiple sclerosis, ADEM, immune-mediate polyradiculoneuropathies, disease-modifying therapies, immunomodulatory therapy
Current Neuropharmacology
Title: Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Volume: 8 Issue: 2
Author(s): Alberto Spalice, Pasquale Parisi, Laura Papetti, Francesco Nicita, Fabiana Ursitti, Francesca Del Balzo, Enrico Properzi, Alberto Verrotti, Martino Ruggieri and Paola Iannetti
Affiliation:
Keywords: Demyelinating disease, pediatric multiple sclerosis, ADEM, immune-mediate polyradiculoneuropathies, disease-modifying therapies, immunomodulatory therapy
Abstract: Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.
Export Options
About this article
Cite this article as:
Spalice Alberto, Parisi Pasquale, Papetti Laura, Nicita Francesco, Ursitti Fabiana, Del Balzo Francesca, Properzi Enrico, Verrotti Alberto, Ruggieri Martino and Iannetti Paola, Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update, Current Neuropharmacology 2010; 8 (2) . https://dx.doi.org/10.2174/157015910791233141
DOI https://dx.doi.org/10.2174/157015910791233141 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Hypotensive Effect of Hydroalcoholic Ziziphus jujuba Extract on Normotensive Rats
Current Nutrition & Food Science Interaction Between Bone and Muscle in Older Persons with Mobility Limitations
Current Pharmaceutical Design Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Diabetes Mellitus during the Pandemic Covid-19: Prevalence, Pathophysiology, Mechanism, and Management: An updated overview
Current Diabetes Reviews The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Anti-Hypertensive Potential and Epigenetics of Angiotensin II type 2 Receptor (AT2R)
Current Hypertension Reviews Subject Index to Volume 10
Current Medicinal Chemistry From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Hydrogen Sulfide as a New Endogenous Gaseous Transmitter in the Cardiovascular System
Current Vascular Pharmacology Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor
CNS & Neurological Disorders - Drug Targets Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets Disulfiram: An Old Therapeutic with New Applications
CNS & Neurological Disorders - Drug Targets Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?
Current Medicinal Chemistry Cysteine-Rich Mini-Proteins in Human Biology
Current Topics in Medicinal Chemistry